ClinicalTrials.gg
CompletedNCT04965506Updated Dec 27, 2023

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

A Phase 2 interventional study of IBI362 and placebo in Type 2 Diabetes, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-27.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
325th of 767
252 · median 199
Started
2021
with 56 others
Phase 2
61 of 909
14 open now
Registered
468th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 325th largest by enrollment of the 767 interventional ones that give a count, is one of 57 that started in 2021, is one of 61 in phase 2, and was the 468th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese patients with Type 2 Diabetes.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have type 2 diabetes (T2DM) for ≥6 months according to the Criteria for Diagnosing Type 2 Diabetes Mellitus (WHO 1999)
  2. T2D patients with poorly controlled blood glucose treated with lifestyle intervention or stable dose of metformin (≥ 1000mg/day or maximum tolerated dose) within 3 months prior to screening.
  3. Have of 7.0% to 10.5%, inclusive(detected by local laboratory at screening).
  4. Have a (BMI) between 20(Inclusive) and 40 kilograms per square meter

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes, special types of diabetes, or gestational diabetes.
  2. Have uncontrolled diabetes defined as more than 2 episodes of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening.
  3. History of severe hypoglycemic episodes within 6 months prior to screening.
  4. Have had any of the following within the last 6 months prior to screening: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), (TIA), cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    IBI362 low dose

    Participants receive low dose IBI362 by subcutaneous (SC) injection once a week.

    Drug: IBI362

  • Experimental
    IBI362 moderate dose

    Participants receive medium dose IBI362 by subcutaneous (SC) injection once a week.

    Drug: IBI362

  • Active comparator
    Dulaglutide

    Participants receive Dulaglutide 1.5mg by subcutaneous (SC) injection once a week.

    Other: Dulaglutide

  • Experimental
    IBI362 high dose

    Participants receive high dose IBI362 by subcutaneous (SC) injection once a week.

    Drug: IBI362

  • Placebo comparator
    placebo

    Participants receive placebo by subcutaneous (SC) injection once a week.

    Other: placebo

Interventions

  • DrugIBI362

    IBI362 administered subcutaneously (SC) once a week.

  • Otherplacebo

    placebo administered subcutaneously (SC) once a week.

  • OtherDulaglutide

    Dulaglutide administered subcutaneously (SC) once a week.

06

What researchers measure

Primary outcomes

  1. The change in HbA1c from baseline to 20 weeks

    Time frame: Baseline,20 weeks

Secondary outcomes

  1. Percentage of Participants Achieving HbA1c Target of <7.0%

    Time frame: Baseline,20 weeks

  2. Number of participants with treatment-related adverse events

    Time frame: Baseline,25 weeks

07

Study locations

1 site
  • China Japan Friendship Hospital
    Beijing, Beijing 100029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Apr 2022, 7 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2021
First posted
Jul 16, 2021
StartActual
Sep 6, 2021
Primary completionActual
Apr 28, 2022
CompletionActual
Jun 11, 2022
Last update
Dec 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04965506
Responsible party
Sponsor
First posted
Jul 16, 2021
Start date
Sep 6, 2021
Primary completion
Apr 28, 2022
Completion
Jun 11, 2022
Last update
Dec 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion